A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS). PS is externalized on cells in the tumor microenvironment when exposed to hypoxia and/or other physiological stressors. On attaching to PS, bavituximab is thought to promote antitumor immunity through its effects on PS receptors in monocytes, and myeloid‐derived suppressor cells, as well as trigger antitumor effects by inducing an antibody‐dependent cellular cytotoxicity on tumor‐associated endothelial cells. We conducted a phase I clinical trial of bavituximab in combination with paclitaxel in patients with HER2‐negative metastatic breast cancer. Patients were treated with weekly paclitaxel (80 mg/m 2 for 3/4 weeks) and weekly bavituximab (3 mg/kg for 4/4 weeks). Correlative studies included the measurement of circulating microparticles, endothelial cells, and apoptotic tumor cells by flow cytometry. Fourteen patients with metastatic breast cancer were enrolled; all were evaluable for toxicity and 13 were evaluable for response. Treatment resulted in an overall response rate (RR) of 85% with a median progression‐free survival (PFS) of 7.3 months. Bone pain, fatigue, headache, and neutropenia were the most common adverse effects. Infusion‐related reactions were the most common adverse event related to bavituximab therapy. Correlative studies showed an increase in the PS‐expressing apoptotic circulating tumor cells in response to bavituximab, but not with paclitaxel. No changes in the number of circulating endothelial cells or apoptotic endothelial cells were observed with therapy. Platelet and monocyte‐derived microparticles decreased after initiation of bavituximab. Bavituximab in combination with paclitaxel is well tolerated for treatment of patients with metastatic breast cancer with promising results observed in terms of clinical RRs and PFS. The toxicity profile of bavituximab is notable for manageable infusion‐related reactions with no evidence for increased thrombogenicity. Recent preclinical data suggest that bavituximab can also promote antitumor immune activity that should be explored in future clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Thrombus Formation
Furie, B., & Furie, B. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801082 · Cited by 1,926 · cited 1×
“P-selectin glycoprotein ligand-1) that can be activated on exposure to injured endothelium leading to coagulopathy and hypercoagulability [27].”
Background
Cited by
Birge, R. B., Boeltz, S., Kumar, S., Carlson, J., Wanderley, J., Calianese, D., Barcinski, M., Brekken, R. A., Huang, X., Hutchins, J. T., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.11 · Cited by 725
Exposure of phosphatidylserine on the cell surface
Nagata, S., Suzuki, J., Segawa, K., & Fujii, T. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.7 · Cited by 512
Molecular Repolarisation of Tumour-Associated Macrophages
Van Dalen, F. J., Van Stevendaal, M. H. M. E., Fennemann, F. L., Verdoes, M., & Ilina, O. (2018) · Molecules · doi:10.3390/molecules24010009 · Cited by 302
Efferocytosis in the tumor microenvironment
Werfel, T. A., & Cook, R. S. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0698-5 · Cited by 156
Regulation of efferocytosis as a novel cancer therapy
Zhou, Y., Yao, Y., Deng, Y., & Shao, A. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00542-9 · Cited by 100
Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis
Wei, Y.-T., Wang, X.-R., Yan, C., Huang, F., Zhang, Y., Liu, X., Wen, Z.-F., Sun, X.-T., Zhang, Y., Chen, Y.-Q., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4260 · Cited by 80
The complex roles of efferocytosis in cancer development, metastasis, and treatment
Tajbakhsh, A., Gheibi hayat, S. M., Movahedpour, A., Savardashtaki, A., Loveless, R., Barreto, G. E., Teng, Y., & Sahebkar, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111776 · Cited by 64
Metadata
- Authors
- Chalasani, P., Marron, M., Roe, D., Clarke, K., Iannone, M., Livingston, R. B., Shan, J. S., & Stopeck, A. T.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2015-03-31
- Volume
- 4
- Issue
- 7
- Pages
- 1051-1059
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W2093827776
- Cited by
- 45
- References
- 1
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.